{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:01:51Z","timestamp":1772712111375,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C3298"],"award-info":[{"award-number":["HI14C3298"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3431-1","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T04:07:20Z","timestamp":1498190840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas"],"prefix":"10.1186","volume":"17","author":[{"given":"KyuHo","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8427-3003","authenticated-orcid":false,"given":"Kyoung-Bun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Yoen","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam-Joon","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Woong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Suk","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja-June","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,23]]},"reference":[{"issue":"1","key":"3431_CR1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00000658-200007000-00003","volume":"232","author":"R Tung-Ping Poon","year":"2000","unstructured":"Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232(1):10\u201324.","journal-title":"Ann Surg"},{"issue":"34","key":"3431_CR2","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.3748\/wjg.v18.i34.4751","volume":"18","author":"JI Lee","year":"2012","unstructured":"Lee JI, Lee JW, Kim JM, Kim JK, Chung HJ, Kim YS. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers. World J Gastroenterol. 2012;18(34):4751\u20137.","journal-title":"World J Gastroenterol"},{"key":"3431_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/1477-3163.151940","volume":"14","author":"YA Ghouri","year":"2015","unstructured":"Ghouri YA, Mian I, Blechacz B. Cancer review: cholangiocarcinoma. J Carcinog. 2015;14:1.","journal-title":"J Carcinog"},{"key":"3431_CR4","volume-title":"WHO classification of tumours of the digestive system","author":"ND Theise","year":"2010","unstructured":"Theise ND, Nakashima O, Park YN, Nakanuma Y. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010.","edition":"4"},{"issue":"3","key":"3431_CR5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/hep.24739","volume":"55","author":"KH Tang","year":"2012","unstructured":"Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, et al. CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin\/interleukin-8\/CXCL1 signaling. Hepatology. 2012;55(3):807\u201320.","journal-title":"Hepatology"},{"issue":"3","key":"3431_CR6","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.gastro.2008.12.004","volume":"136","author":"T Yamashita","year":"2009","unstructured":"Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem\/progenitor cell features. Gastroenterology. 2009;136(3):1012\u201324.","journal-title":"Gastroenterology"},{"key":"3431_CR7","unstructured":"Zamboni G KG, Hruban RH. WHO classification of tumours. Pathology and Genetics of Tumours of the Digestive System. 3rd edn. Lyon: IARC Press; 2000."},{"issue":"2","key":"3431_CR8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jhbp.154","volume":"22","author":"S Aishima","year":"2015","unstructured":"Aishima S, Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci. 2015;22(2):94\u2013100.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"7","key":"3431_CR9","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/his.12342","volume":"64","author":"AW Chan","year":"2014","unstructured":"Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology. 2014;64(7):935\u201350.","journal-title":"Histopathology"},{"issue":"5","key":"3431_CR10","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/hep.24559","volume":"54","author":"H Kim","year":"2011","unstructured":"Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, et al. Human hepatocellular carcinomas with \u201cStemness\u201d-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54(5):1707\u201317.","journal-title":"Hepatology"},{"key":"3431_CR11","unstructured":"Zhu Q, Gurda G. YAP1 (yes-associated protein 1). Pancreapedia: The Exocrine Pancreas Knowledge Base 2014. http:\/\/ http:\/\/www.pancreapedia.org\/molecules\/yap1-yes-associated-protein-1 . Accessed 15 Oct 2014."},{"issue":"6","key":"3431_CR12","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cell.2014.03.060","volume":"157","author":"D Yimlamai","year":"2014","unstructured":"Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157(6):1324\u201338.","journal-title":"Cell"},{"issue":"10","key":"3431_CR13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.dld.2015.05.011","volume":"47","author":"Q Nguyen","year":"2015","unstructured":"Nguyen Q, Anders RA, Alpini G, Bai H. Yes-associated protein in the liver: regulation of hepatic development, repair, cell fate determination and tumorigenesis. Dig Liver Dis. 2015;47(10):826\u201335.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"3431_CR14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s12253-014-9757-y","volume":"20","author":"XB Hu","year":"2014","unstructured":"Hu XB, Xin Y, Xiao YP, Zhao J. Overexpression of YAP1 is correlated with progression, metastasis and poor prognosis in patients with gastric carcinoma. Pathology & Oncology Research. 2014;20(4):805\u201311.","journal-title":"Pathology & Oncology Research"},{"issue":"2","key":"3431_CR15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2014.08.036","volume":"355","author":"M Li","year":"2014","unstructured":"Li M, Lu J, Zhang F, Li H, Zhang B, Wu X, et al. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL\/MAPK pathway. Cancer Lett. 2014;355(2):201\u20139.","journal-title":"Cancer Lett"},{"issue":"7","key":"3431_CR16","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1053\/j.gastro.2013.02.009","volume":"144","author":"DF Tschaharganeh","year":"2013","unstructured":"Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, et al. Yes-associated protein up-regulates jagged-1 and activates the notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013;144(7):1530\u201342. e1512","journal-title":"Gastroenterology"},{"issue":"8","key":"3431_CR17","volume":"10","author":"ZQ Sun","year":"2015","unstructured":"Sun ZQ, Xu RW, Li XY, Ren WG, Ou CL, Wang QS, et al. Prognostic value of yes-associated protein 1 (YAP1) in various cancers: a meta-analysis. PLoS One. 2015;10(8):e0135119.","journal-title":"PLoS One"},{"issue":"7430","key":"3431_CR18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature11693","volume":"493","author":"ER Barry","year":"2013","unstructured":"Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature. 2013;493(7430):106\u201310.","journal-title":"Nature"},{"issue":"6","key":"3431_CR19","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471\u20134.","journal-title":"Ann Surg Oncol"},{"key":"3431_CR20","doi-asserted-by":"crossref","unstructured":"Japan LCSGo. The general rules for the clinical and pathological study of primary liver cancer. Jpn J Surg 1989;19(1):98\u2013129.","DOI":"10.1007\/BF02471576"},{"issue":"6","key":"3431_CR21","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jhep.2015.07.008","volume":"63","author":"D Yimlamai","year":"2015","unstructured":"Yimlamai D, Fowl BH, Camargo F. Emerging evidence on the role of the Hippo\/YAP pathway in liver physiology and cancer. J Hepatol. 2015;63(6):1491\u2013501.","journal-title":"J Hepatol"},{"issue":"6","key":"3431_CR22","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cell.2014.03.060","volume":"157","author":"D Yimlamai","year":"2014","unstructured":"Yimlamai D, Christodoulou C, Galli Giorgio G, Yanger K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157(6):1324\u201338.","journal-title":"Cell"},{"issue":"7","key":"3431_CR23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.cell.2006.05.030","volume":"125","author":"L Zender","year":"2006","unstructured":"Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125(7):1253\u201367.","journal-title":"Cell"},{"issue":"12","key":"3431_CR24","doi-asserted-by":"crossref","first-page":"10102","DOI":"10.18632\/oncotarget.3546","volume":"6","author":"X Li","year":"2015","unstructured":"Li X, Tao J, Cigliano A, Sini M, Calderaro J, Azoulay D, et al. Co-activation of PIK3CA and yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget. 2015;6(12):10102\u201315.","journal-title":"Oncotarget"},{"issue":"5","key":"3431_CR25","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2014.06.033","volume":"61","author":"A Perra","year":"2014","unstructured":"Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61(5):1088\u201396.","journal-title":"J Hepatol"},{"issue":"3","key":"3431_CR26","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1053\/j.gastro.2014.05.004","volume":"147","author":"J Tao","year":"2014","unstructured":"Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, et al. activation of \u03b2-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014;147(3):690\u2013701.","journal-title":"Gastroenterology"},{"issue":"9","key":"3431_CR27","volume":"8","author":"GJ Kim","year":"2013","unstructured":"Kim GJ, Kim H, Park YN. Increased expression of yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS One. 2013;8(9):e75449.","journal-title":"PLoS One"},{"issue":"6","key":"3431_CR28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000370252","volume":"31","author":"H Li","year":"2014","unstructured":"Li H, Wang SH, Wang GY, Zhang ZG, Wu XC, Zhang T, et al. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. Dig Surg. 2014;31(6):468\u201378.","journal-title":"Dig Surg"},{"issue":"19","key":"3431_CR29","doi-asserted-by":"crossref","first-page":"17206","DOI":"10.18632\/oncotarget.4043","volume":"6","author":"T Pei","year":"2015","unstructured":"Pei T, Li Y, Wang J, Wang H, Liang Y, Shi H, et al. YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget. 2015;6(19):17206\u201320.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3431-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T14:05:07Z","timestamp":1569506707000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3431-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,23]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3431"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3431-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,23]]},"article-number":"441"}}